Literature DB >> 6326778

A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study.

M Poisson, F Huguet, A Savattier, F Bakri-Logeais, G Narcisse.   

Abstract

4,4-Dimethyl-1-[3,4-(methylenedioxy)-phenyl]-1-penten-3-ol (stiripentol), selected from a series of alpha-ethylene alcohols, demonstrated anticonvulsant activity in studies in the rat and rabbit in which convulsions were induced electrically and chemically using pentetrazol, bicuculline and strychnine. Neurochemical studies showed that stiripentol in vitro did not act as a GABA receptor agonist, instead it inhibited the synaptosomal uptake of 3H-labelled GABA. Stiripentol has been shown elsewhere to inhibit GABA transaminase. These findings suggest that the anticonvulsant activity of stiripentol involves two aspects of the GABAergic mechanism in which the metabolic transamination and synaptosomal uptake of this neurotransmitter are inhibited.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326778

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

Review 1.  Stiripentol.

Authors:  Catherine Chiron
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants.

Authors:  A V Boddy; K Zhang; F Lepage; F Tombret; J G Slatter; T A Baillie; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

Review 3.  Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).

Authors:  Greg L Plosker
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 4.  Recent Advances in the Drug Treatment of Dravet Syndrome.

Authors:  Elaine C Wirrell; Rima Nabbout
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

5.  The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator.

Authors:  Janet L Fisher
Journal:  Neuropharmacology       Date:  2008-06-10       Impact factor: 5.250

Review 6.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 7.  New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.

Authors:  M Bebin; T P Bleck
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

8.  A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form.

Authors:  Hany W Darwish; Ali S Abdelhameed; Mohamed I Attia; Ahmed H Bakheit; Nasr Y Khalil; Abdulrahman A Al-Majed
Journal:  J Anal Methods Chem       Date:  2014-10-14       Impact factor: 2.193

9.  New developments in the treatment of partial-onset epilepsy.

Authors:  Frank Mc Besag; Philip N Patsalos
Journal:  Neuropsychiatr Dis Treat       Date:  2012-10-17       Impact factor: 2.570

10.  Solid Dispersion Approach Improving Dissolution Rate of Stiripentol: a Novel Antiepileptic Drug.

Authors:  Samar Afifi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.